Clinical Education
Center
  1. VIDEO TRANSCRIPT: ​​Looping video of falling confetti and ​two QWO vials sitting on a white table.

    A Cutting Edge Treatment for Cellulite Without the Cutting

    Now Available

    Qwo® may be a game changer for your aesthetics practice.1,2 It is the first and only FDA-approved injectable treatment for moderate to severe cellulite in the buttocks of adult women.

    Get QWO
  2. ​
    ​​Comparison of a woman’s buttocks before QWO treatment and at Day 71.

    Primary Efficacy Endpoint: Two-grade or better improvement measured by both physician and patient rated photonumeric cellulite severity score assessments occurred in 7.6% (P=.006) of patients.3 Phase 3 subject images. Individual results may vary.

    Visible Results You Can Get Behind

    Qwo® provides an opportunity to help appropriate patients who are bothered by their moderate to severe cellulite in the buttocks.1

    See Real Results
    ​​Comparison of a woman’s buttocks before QWO treatment and at Day 71.

    Primary Efficacy Endpoint: Two-grade or better improvement measured by both physician and patient rated photonumeric cellulite severity score assessments occurred in 7.6% (P=.006) of patients.3 Phase 3 subject images. Individual results may vary.

  3. Healthcare professional showing a patient information on an iPad. Healthcare professional showing a patient information on an iPad.

    Paid models. Not actual patient.

    Cellulite Affects Approximately 90% of Women4

    But are they ready to talk about it? In a recent online Harris Poll conducted with over 2,000 women with cellulite (ages 18-59), most women (89%) indicated that they are ready to talk to you about their cellulite.5

    Patient Selection

    Paid models. Not actual patient.

  4. VIDEO TRANSCRIPT: ​​Looping video depicting a needle penetrating dermis.

    Perceived Mechanism of Action

    Enzymatic Subcision & Remodeling™

    While the exact mechanism for the treatment of moderate to severe cellulite is unknown, Qwo® is believed to initiate a process called Enzymatic Subcision and Remodeling (ESR™).1,2

    Watch the Video

As seen on

Carousel items

  1. Shape logo.
  2. ELLE logo.
  3. NEWBEAUTY logo.
  4. Bloomberg logo.
  5. MedScape logo.

The Opportunity for Your Practice

The QWO Difference:

Syringe.

First and only FDA-approved injectable treatment for moderate to severe cellulite in the buttocks of adult women

Icon of outline of buttocks.

Visible results 28 days after the third treatment (21 days apart).1,3*

Icon of person standing next to clock.

In the clinical trials, no post-treatment downtime was required.6

Icon of the three areas associated with cellulite.

The exact mechanism for the treatment of moderate to severe cellulite is unknown.1

*In clinical trials, efficacy was assessed at Day 71. Individual results may vary.

“I am thrilled there is now an FDA-approved injectable treatment option for cellulite to offer to my patients.”

–––– Anne Chapas, MD

Ready for QWO?

Sign up to learn more about bringing QWO into your practice.

I'm Ready

Indication

Qwo® is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

Important Safety Information for QWO

Contraindications

QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

Warnings and Precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions including anaphylaxis have been reported with the use of collagenase clostridium histolyticum. If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

Injection Site Bruising

In clinical trials, 84% of subjects treated with QWO experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking ≤150 mg aspirin daily) were excluded from participating in Trials 1 and 2.

QWO should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet (except those taking ≤150 mg aspirin daily) or anticoagulant therapy.

Substitution of Collagenase Products

QWO must not be substituted with other injectable collagenase products.

QWO is not intended for the treatment of Peyronie’s Disease or Dupuytren’s Contracture.

Adverse Reactions

In clinical trials, the most commonly reported adverse reactions in patients treated with QWO with an incidence ≥ 10% were at the injection site: bruising, pain, nodule and pruritus.

View Full Prescribing Information for QWO.